Table 1. Patients’ characteristics.

Record #	Gender	Smoking history	EGFR mutation type	Differentiation status at diagnosis	Stage at SCLC transformation	RB1 loss	TP53 mutation	WNK1 mutation	Duration from the initial diagnosis to transformation (Months)	PFS after EP/EC chemotherapy (Months)	Post-EP/EC chemotherapy survival (Months)	Duration of TKIs after transformation (Months)
1	Male	Former smoker	Exon 19	Poor	Limited	No	Yes	Yes	5.7	29.0	53.6+	53.6+
2	Male	Never smoker	Exon 19	Poor	Extensive	Yes	Yes	Yes	19.5	7.7	19.0+	19.0+
3	Female	Never smoker	Exon 21	Moderate-to-poor	Extensive	No	Yes	No	22.7	2.3	3.5	0.9
4	Male	Former smoker	Exon 19	Poor	Extensive	Yes	Yes	No	10.6	5.3	7.5+	N/A
5	Female	Former smoker	Exon 19	Poor	Limited	Yes	Yes	No	19.8	1.8	8.6	8.6
6	Female	Never smoker	Exon 19	Moderate-to-poor	Limited	Yes	Yes	No	30.2	3.2	9.6	4.7
7	Male	Former smoker	Exon 19	Poor	Extensive	Yes	Yes	No	24.6	5.0	19.0	19.0
8	Female	Never smoker	Exon 21	Poor	Extensive	N/A	Yes	No	24.9	2.5	2.8	N/A
9	Female	Former smoker	Exon 19	Poor	Limited	N/A	Yes	No	25.2	2.0	4.5	N/A

All patients were stage IV with ADC. EGFR, epidermal growth factor receptor; AJCC, American Joint Committee on Cancer; RB1, retinoblastoma 1; SCLC, small cell lung cancer; TP53, tumor protein p53; WNK1, WNK lysine deficient protein kinase 1; PFS, progression-free survival; EP, etoposide/cisplatin; EC, etoposide/carboplatin; TKIs, tyrosine kinase inhibitors; N/A, not applicable; ADC, adenocarcinoma.